SeekInCure - SeekIn

SeekInCure®

The first-in-class blood-based pan-cancer recurrence monitoring test

SeekInCure® is applied to monitoring cancer recurrence and risk evaluation for post-op cancer patients. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer patients continually, combined with plasma protein markers, equipping big data and artificial intelligence, it generates cancer recurrence index (CRI) .

A panoramic view of cancer genomic landscape

cfDNA detection via NGS drawing the view of cancer genomic landscape

Cutting-edge multivariate algorithm

Genomics combined with proteomics，capturing the signal of cancer recurrence

Multidimensional fingerprint

CNA, Fragmentation and protein markers discovering the early cancer recurrence

Big date and Artificial intelligence

CRI model based on machine learning evaluating the risk of cancer recurrence precisely

Specifications

◉ Indicated subjects: post-surgery cancer patients◉ Sample requirement: 10ml peripheral blood◉ Result readout: CRI (cancer recurrence index)◉ TAT: 10 working days Sampling time:

How it works 

Pre-test inquiry

Informed consent 

Blood-draw

 Testing

Analyzing + Interpretation

Reporting